Top Markets
#1 Islamic Coin Islamic Coin +154.46%
#2 PulseChain PulseChain +48.38%
#3 Ergo Ergo +29.15%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.40%
#5 RedStone RedStone +16.30%
#6 SkyAI SkyAI +10.37%
#7 Lighter Lighter +9.20%
#8 OPENLOOT OPENLOOT +8.93%
#9 Siren Siren +8.92%
#10 MarsCoin MarsCoin +8.84%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Genenta Science S.p.A. Genenta Science S.p.A.

Genenta Science S.p.A.

GNTA
Rank in Stocks #28070
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused... Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Share Price
$1.51
Last synced: 2026-07-31
Market Cap
$28.82M
Change (1 day)
-0.33%
Change (1 year)
-57.49%
Country
IT
Trade Genenta Science S.p.A. (GNTA)

Category

Healthcare
P/E ratio for Genenta Science S.p.A. (GNTA)
P/E ratio as of 2026 TTM: 0
According to Genenta Science S.p.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Genenta Science S.p.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.